



Company Overview

Achillion is an innovative biopharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company's highly skilled and experienced discovery and development teams have discovered and advanced multiple

product candidates, many with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease including hepatitis C and resistant bacterial infections.

Product Pipeline

INFECTIOUS DISEASE COMPOUND	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
FOR HCV INFECTION					
ACH-1625					
ACH-2684					
ACH-2928					
ACH-1095					
FOR BACTERIAL INFECTION					
ACH-702					

Achillion's proprietary discovery efforts have resulted in a clinical candidate nomination rate of more than one compound per year. Achillion's broadly-skilled research and clinical scientists currently are advancing three of these compounds into and through the clinic, with significant value-accreting milestones planned for each compound in 2011.

Achillion Highlights

- Three distinct HCV programs, all aimed at this major market, anticipated to reach \$10B in 2012
 - Most advanced compound in phase 2 clinical trials
 - Two additional compounds in phase 1 clinical trials beginning mid-2011
 - Combinability of these compounds provides multiple strategic options for future development
- Additional antibacterial compounds, including those effective against MRSA, are advancing under grant arrangements
- Exceptional discovery platform – All HCV and antibacterial compounds discovered and developed entirely at Achillion

Significant Opportunities

HCV Market

- HCV infection is a significant and increasing disease burden with 170 million people infected worldwide
- Currently available therapies resulted in \$2B in worldwide sales in 2004. With introduction of new therapies, market anticipated to grow to over \$10B in 2012
- Current standard of care has significant limitations:
 - Efficacy against HCV genotype I (majority of market) is ~50%
 - Significant adverse events associated with interferon and ribavirin

Antibacterials Market

- 70% of hospital-based infections are resistant to at least one antibiotic
- Only two new classes of antibacterials marketed since 1968
- Current antibacterials are limited by:
 - Potency
 - Lack of a bactericidal (bacteria-killing) mechanism of action
 - Narrow spectrum of activity
 - Intravenous or injection required
 - Adverse side effects

HCV Programs

Achillion's HCV approach is multi-fold: First, focusing on a clinically proven target, the HCV protease, Achillion has discovered and is developing ACH-1625, a clinically-proven compound with an excellent safety profile and unique pharmacokinetics.

Achillion has also discovered and is advancing ACH-2684, a high-potency HCV inhibitor with pan-genotypic activity and pico-molar potency against both common and naturally-occurring mutations.

In addition, Achillion is studying ACH-2928, a potent inhibitor of HCV NS5A with good safety and pharmacokinetic profiles, and that operates synergistically with ACH-1625, as well as other compounds.

ACH-1625 ADVANTAGES

- **Pharmacokinetics.** With its rapid and extensive partitioning to the liver, as well as high liver/plasma ratios, ACH-1625 has been clinically demonstrated to have once daily dosing.
- **Virology.** ACH-1625 has shown low single-digit nanomolar potency that is specific to HCV. It is equipotent against HCV genotypes 1a and 1b at IC50 ~1nM.
- **Safety.** High safety margins established in both single ascending dose and repeat dose studies. Overall, the compound is well-tolerated with minimal side effects, in both volunteers and HCV patients.

ACH-2684 ADVANTAGES

- **Potency.** With potency in the low pico-molar range, ACH-2684 is ten to twenty fold more potent than other HCV inhibitors under development.
- **Combination Use.** It has been demonstrated in vitro that ACH-2684 can be used in combination with other HCV inhibitors, and that it is synergistic with NS5B nucleoside polymerase inhibitors.
- **Virology.** ACH-2684 demonstrates that it very effectively suppresses a broad range of natural variants of the hepatitis C virus, and may be effective in prevention and treatment of emerging resistant variants. The compound retains potent activity against all genotypes 1 through 6.

ACH-2928 ADVANTAGES

- **Potency.** ACH-2928 has demonstrated excellent potency against HCV RNA replication in all genotypes at concentrations ranging from 2 – 20pM.
- **Combinability.** ACH-2928 is highly effective in combination with NS3 protease inhibitors, NS5B polymerase inhibitors, interferon and ribavirin. It is highly **synergistic** with Achillion's protease inhibitor, ACH-1625.
- **Pharmacokinetics.** ACH-2928 is anticipated to be dosed once-daily without boosting.
- **Safety.** ACH-2928 has demonstrated a good safety profile at high doses.

Antibacterial Programs

Achillion has discovered and is advancing ACH-702 and ACH-2881, as well as other compounds, for the treatment of serious bacterial infections.

Based on preclinical study data, Achillion believes that ACH-2881 may play an important role in the fight against drug-resistant bacteria, particularly MRSA.

Leadership

MANAGEMENT TEAM

Michael D. Kishbauch
President and
Chief Executive Officer

Milind S. Deshpande, Ph.D.
President and
Chief Scientific Officer

Gautam Shah, Ph.D.
Senior Vice President and
Chief Compliance Officer

Mary Kay Fenton
Senior Vice President and
Chief Financial Officer

Elizabeth Olek, D.O.
Senior Vice President of
Clinical Development and
Chief Medical Officer

Joseph Truitt
Vice President of Business
Development and
Chief Commercial Officer

BOARD OF DIRECTORS

Jason Fisherman, M.D.
Managing Director
Advent Healthcare Ventures

Gary E. Frashier
Principal
Management Associates

Michael D. Kishbauch
President and
Chief Executive Officer
Achillion Pharmaceuticals, Inc.

Dennis Liotta, Ph.D.
Professor
Emory University

David I. Scheer
President
Scheer & Co., Inc.

Nicholas Simon
Managing Director
Clarus Ventures

Robert L. Van Nostrand
Management Consultant

Nicole Vitullo
Partner
Domain Associates

David P. Wright
President
CWD Enterprises

Contact Information

Achillion Pharmaceuticals, Inc.
300 George Street
New Haven, CT 06511

Main phone: (203) 624-7000
Main fax: (203) 624-7003
Email: info@achillion.com

NASDAQ Symbol: ACHN

Investors
Mary Kay Fenton
Achillion Pharmaceuticals, Inc.
IR@achillion.com

Corporate Contact
Glenn Schulman
Achillion Pharmaceuticals, Inc.
gschulman@achillion.com
(203) 624-7000

Business Development
Joseph Truitt
Achillion Pharmaceuticals, Inc.
businessdevelopment@achillion.com